Aileron Therapeutics Unveils New Therapeutic Drug Program; Appoints Hubert C. Chen, M.D., to Vice President of Clinical Development
9/6/2012 10:18:00 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aileron Therapeutics, Inc. today announced the appointment of Hubert C. Chen, M.D., to vice president of clinical development, endocrine and metabolic disease. This strategic appointment comes as Aileron expands into endocrine and metabolic diseases and prepares to initiate clinical development in early 2013 of its first Stapled Peptide drug candidate, ALRN-5281, a proprietary, long-acting growth-hormone-releasing hormone (GHRH) agonist for treating orphan disorders including adult growth hormone (GH) deficiency and HIV lipodystrophy, as well as broader patient populations such as GH-deficient abdominal obesity.
comments powered by